I-Corps: Injectable, Highly Sticky, Antimicrobial, and Hemostatic Adhesive for Cornea Injury Repair

I-Corps：用于角膜损伤修复的可注射、高粘性、抗菌和止血粘合剂

• 批准号: 1848656
• 负责人: Iman Noshadi
• 金额: $ 5万
• 依托单位: Rowan University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-15 至 2019-02-28
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1848656&HistoricalAwards=false
• 关键词: Corps; Injectable; Highly; Sticky; Antimicrobial

The broader impact/commercial potential of this I-Corps project targets treatment of ocular trauma, in particular corneal injuries. Ocular trauma treatment requires advanced surgical equipment and specialty surgical centers. The Corneal Transplant Market, currently at 40000 per year in the US is expected to grow at 10.8% from 2017 to 2023. The project targets the wound care market of $18.22 billion (2016), expected to reach $26.24 billion (2023). The societal impact entails enabling rapid care provision to patients like soldiers in combat, to trauma and elderly and pediatric patients, as well as reduction of operative and post-operative costs. The technology can be extended to repairing tissues such as lung, liver, heart or kidneys, expanding its reach and medical benefits to larger populations. This novel chemistry platform aims toward tissue adhesion, but the chemistry could be slightly altered to make materials for a broader range of biomedical applications. Study of such novel material platforms, like understanding of structure-property relationships, offers numerous teaching and outreach opportunities involving students from subject disciplines spanning chemistry, material sciences, chemical, mechanical, and electrical engineering to biology. This I-Corps project has developed a modified hydrogel to make antimicrobial, hemostatic and highly adhesive glue for surgical applications. This is a material platform to make cost-effective, sutureless, and user-friendly adhesives to heal injury to biological tissue and save operative and post-operative time and cost. The current primary needs for ocular trauma surgery entail operative and postoperative time and cost reduction. Currently, there are no such Food and Drug Administration-approved material platforms to replace the presently used techniques of suturing effectively. The material is expected to enjoy biocompatibility, biodegradability, no toxicity and excellent adhesion to tissues, even in the presence of body fluids. The platform may also aid in blood coagulation, facilitate healing and inhibit bacterial growth. This innovation will potentially circumvent the limitations of current surgical and post-operative approaches in corneal repair, and in the future may be extended to repair of other human tissues.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目的更广泛的影响/商业潜力靶向治疗眼部创伤，特别是角膜损伤。眼部创伤治疗需要先进的手术设备和专业手术中心。目前，美国每年为40000的角膜移植市场预计从2017年到2023年增长10.8％。该项目的目标是增长182.2亿美元（2016年），预计将达到262.4亿美元（2023年）。社会影响需要为战斗中的士兵，创伤，老年人和儿科患者以及降低手术和术后费用的士兵提供快速护理提供。该技术可以扩展到修复肺，肝脏，心脏或肾脏等组织，从而将其覆盖范围和医疗益处扩大到较大的人群。这个新颖的化学平台旨在朝着组织粘附，但是可以稍微改变化学，以制造更广泛的生物医学应用材料。研究此类新型材料平台的研究，例如了解结构 - 陶艺关系，提供了许多教学和推广机会，这些教学和外展机会涉及来自学科的学生，涉及化学，物质科学，化学，机械和电气工程到生物学的学科。 这个I-Corps项目已开发出一种改良的水凝胶，以使手术应用制造抗菌，止血和高度粘合剂胶。这是一个物质平台，可以使具有成本效益，无用和用户友好的粘合剂治愈生物组织的伤害，并节省手术和术后时间和成本。目前对眼部创伤手术的主要需求包括手术和术后时间和成本降低。当前，尚无此类食品药品监督管理局批准的材料平台来有效替代目前使用的缝合技术。即使在存在体液的情况下，该材料有望具有生物相容性，生物降解性，无毒性和对组织的良好粘附。该平台还可能有助于血液凝血，促进愈合并抑制细菌的生长。这项创新将有可能避免角膜修复中当前手术和术后方法的局限性，将来可能会扩展以修复其他人类组织。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子优点和更广泛的影响审查标准来通过评估来获得支持的。